PMID: 7011000Jan 1, 1980Paper

Detection of platelet associated IgG in immune thrombocytopenia: a new assay employing protein A and peroxidase anti-peroxidase (PROA-PAP)

American Journal of Hematology
D Y TateR L Sorenson

Abstract

Immune thrombocytopenia is frequently encountered in medical practice and is generally accepted as being caused by an IgG antibody. The capability of detecting platelet-bound IgG as a diagnostic and therapeutic modality is critical for appropriate care and management of patients with idiopathic thrombocytopenic purpura (ITP), as well as other immune thrombocytopenias. We have modified our previous assay (Br J Haematol 37:265, 1977) by employing protein A and PAP as a labeled antibody. Surface bound platelet IgG was quantitated by phase contrast microscopy after incubation with PAP, graded per 100 platelets and expressed as a reactive index (RI). Controls (n=13) had RIs ranging from 0.49 to 0.72 (mean 0.63 +/- 0.02 SE). The nonimmune thrombocytopenic group (n=7) had an RI ranging from 0.58 to 0.72 (mean 0.64 +/- 0.01 SE). In contrast, the immune thrombocytopenic group (n=28) had RIs ranging from 1.04 to 1.75 (mean 1.43 +/- ;0.03 SE). Platelet-associated IgG was evaluated further by absorbing representative sera samples from each group against washed granulocytes, red cells and platelets. Only when sera from the immune thrombocytopenic group were absorbed against platelets did the reactive indices of pre- and postabsorption sampl...Continue Reading

References

Jun 1, 1978·British Journal of Haematology·A E von dem BorneC P Engelfriet
Apr 5, 1979·The New England Journal of Medicine·J G KeltonJ Hirsh
Jan 18, 1979·The New England Journal of Medicine·D B Cines, A D Schreiber
Oct 1, 1978·Scandinavian Journal of Haematology·C J Pascual, E Romano
Feb 1, 1979·The Journal of Pediatrics·A L LightseyJ R Stone
Jan 1, 1977·British Journal of Haematology·U M HegdeS Worlledge
Apr 1, 1975·British Journal of Haematology·P Ganguly
Nov 1, 1973·Clinical Immunology and Immunopathology·S KarpatkinG W Siskind
Nov 28, 1974·The New England Journal of Medicine·N AbramsonR H Aster
May 2, 1974·The New England Journal of Medicine·R I Handin, T P Stossel
Dec 1, 1974·Proceedings of the Society for Experimental Biology and Medicine·S KarpatkinM B Zucker
Dec 1, 1972·The Journal of Clinical Investigation·D Deykin, L J Hellerstein
Jan 31, 1974·The New England Journal of Medicine·R McMillanR Yelenosky
Mar 23, 1972·The New England Journal of Medicine·R ClancyB Firkin
Jun 30, 1965·Annals of the New York Academy of Sciences·M Baldini

❮ Previous
Next ❯

Citations

Jan 1, 1993·Intensive Care Medicine·K MaruyamaM Muneyuki
Nov 1, 1985·British Journal of Haematology·J G Kelton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Advances in Neonatal Care : Official Journal of the National Association of Neonatal Nurses
Cindy K BarneyRobert D Christensen
The Journal of Surgical Research
L OppenheimerA J Bishop
© 2021 Meta ULC. All rights reserved